TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR) MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 56
2 MARKET SEGMENTATION 59
2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT TYPE LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET APPLICATION COVERAGE GRID 68
2.11 VENDOR SHARE ANALYSIS 69
2.12 SECONDARY SOURCES 70
2.13 ASSUMPTIONS 70
3 EXECUTIVE SUMMARY 71
4 PREMIUM INSIGHTS 73
4.1 PORTERS FIVE FORCES 74
4.2 PESTEL ANALYSIS 75
4.3 MICRO AND MACRO ECONOMIC FACTORS 76
4.4 PENETRATION AND GROWTH PROSPECT MAPPING 76
4.5 KEY PRICING STRATEGIES 77
5 REGULATORY COMPLIANCE 78
5.1 REGULATORY AUTHORITIES 78
5.2 REGULATORY CLASSIFICATIONS 78
5.3 REGULATORY SUBMISSIONS 78
5.4 INTERNATIONAL HARMONIZATION 79
5.5 COMPLIANCE AND QUALITY MANAGEMENT SCENARIO 80
5.6 REGULATORY CHALLENGES AND STRATEGY 81
6 MARKET OVERVIEW 82
6.1 DRIVERS 84
6.1.1 RISE IN AVAILABILITY OF DIGITAL PCR DIAGNOSTICS 84
6.1.2 INCREASING APPLICATION OF DIGITAL PCR 84
6.1.3 INCREASING DEMAND FOR PERSONALIZED MEDICINE 85
6.2 RESTRAINTS 85
6.2.1 LIMITATIONS IN ANALYZING NOVEL COMPLEX DEVICES 85
6.2.2 HIGH COST OF DIGITAL PCR DEVICES 86
6.3 OPPORTUNITIES 86
6.3.1 RISING FREQUENCY OF INFECTIOUS DISEASES 86
6.3.2 RISING PRODUCT INNOVATIONS THROUGH R&D ACTIVITIES 86
6.4 CHALLENGES 87
6.4.1 STRINGENT REGULATIONS AND LEGAL CHALLENGES FOR DIGITAL PCR 87
6.4.2 LACK OF SKILLED PROFESSIONALS PERFORMING DIGITAL PCR 87
7 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR)MARKET, BY PRODUCT TYPE 89
7.1 OVERVIEW 90
7.2 DIGITAL PCR INSTRUMENTS 93
7.2.1 BY MODALITY 93
7.2.1.1 STANDLONE 93
7.2.1.2 PORTABLE 93
7.2.2 BY METHOD 93
7.2.2.1 PLATE-BASED DPCR 94
7.2.2.2 CHIP BASED DPCR 94
7.2.2.3 MICROFLUIDIC CHAMBER BASED DPCR 94
7.2.2.4 OTHERS 94
7.3 CONSUMABLES AND REAGENTS 94
7.3.1 REAGENTS 94
7.3.1.1 DNA OR PCR TEMPLATES 95
7.3.1.2 DNA POLYMERASE ENZYME 95
7.3.1.3 PRIMERS 95
7.3.1.4 DEXOYNUCLEOTIDE TRIPHOSPHATES (DNTPS) 95
7.3.1.5 PCR BUFFERS 95
7.3.1.6 PCR KIT 95
7.3.2 CONSUMABLES 96
7.3.2.1 PLATES 96
7.3.2.2 TUBES & CAPS 96
7.3.2.3 PLASTIC ACCESSORIES 96
7.3.2.4 PLATE SEALS 96
7.3.2.5 CARTRIDGES 97
7.3.2.6 OTHERS 97
7.4 SOFTWARE AND SERVICES 97
8 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR)MARKET, BY TECHNOLOGY 98
8.1 OVERVIEW 99
8.2 DROPLET DIGITAL PCR 102
8.2.1 CLINICAL 102
8.2.2 LIFE SCIENCE & RESEARCH 102
8.2.3 OTHERS 102
8.3 BEAMING DIGITAL PCR 103
8.3.1 CLINICAL 103
8.3.2 LIFE SCIENCE & RESEARCH 103
8.3.3 OTHERS 103
9 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR)MARKET, BY APPLICATION 104
9.1 OVERVIEW 105
9.2 CLINICAL 108
9.2.1 ONCOLOGY TESTING 108
9.2.2 INFECTIOUS DISEASE TESTING 108
9.2.2.1 HIV 109
9.2.2.2 HCV 109
9.2.2.3 HEPATITIS B VIRUS 109
9.2.2.4 HUMAN PAPILLOMAVIRUS 109
9.2.2.5 OTHERS 109
9.2.3 BLOOD SCREENING 109
9.2.4 TRANSPLANT DIAGNOSTICS 109
9.3 LIFE SCIENCE & RESEARCH 110
9.3.1 MICROBIOLOGY 110
9.3.2 MOLECULAR AND CELL BIOLOGY 110
9.3.3 OTHERS 110
9.4 OTHERS 110
10 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN (PCR) REACTION MARKET, BY END USER 111
10.1 OVERVIEW 112
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 115
10.3 HOSPITALS AND CLINICS 115
10.3.1 PRIVATE 115
10.3.1.1 TIER 1 115
10.3.1.2 TIER 2 116
10.3.1.3 TIER 3 116
10.3.2 PUBLIC 116
10.3.2.1 TIER 1 116
10.3.2.2 TIER 2 116
10.3.2.3 TIER 3 116
10.4 DIAGNOSTIC LABORATORIES 117
10.5 ACADEMIC AND RESEARCH ORGANIZATIONS 117
10.6 REFERENCE LABORATORIES 117
10.7 OTHERS 117
11 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR) MARKET, BY DISTRIBUTION CHANNEL 118
11.1 OVERVIEW 119
11.2 DIRECT TENDER 122
11.3 RETAIL SALES 122
11.4 OTHERS 122
12 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR) MARKET, BY REGION 123
12.1 MIDDLE EAST AND AFRICA 124
13 MIDDLE EAST & AFRICA DIGITAL POLYMERASE CHAIN REACTION (PCR) MARKET, COMPANY LANDSCAPE 167
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 167
14 SWOT ANALYSIS 168

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.